NCT04121442View on ClinicalTrials.gov

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

July 15, 2024

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

Isunakinra

Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling

BIOLOGICAL

PD-(L)1 Inhibitor

Monoclonal antibody targeting PD-1 or PD-L1

Trial Locations (1)

75246

Baylor Charles A. Simmons Cancer Center, Dallas

Sponsors

Collaborators (1)

Baylor Research Institute
All Listed Sponsors
collaborator

Baylor Research Institute

OTHER

lead

Buzzard Pharmaceuticals

INDUSTRY